PLAUR and ovarian carcinoma: IMD-4482 treatment decreased PAI-1 expression in ovarian cancer cells in a dose-dependent manner (relative PAI-1 expression: SKOV3ip1: 1 μM, 0.91 ± 0.14, 3 μM, 0.82 ± 0.10, 10 μM, 0.71 ± 0.06; HeyA8: 1 μM, 0.90 ± 0.05, 3 μM, 0.81 ± 0.03, 10 μM, 0.45 ± 0.05), while it did not decrease uPAR expression (Figure 2D).